<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168831</url>
  </required_header>
  <id_info>
    <org_study_id>205.255</org_study_id>
    <nct_id>NCT00168831</nct_id>
  </id_info>
  <brief_title>Tiotropium / Respimat One-Year Study</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the
      Respimat inhaler in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 After 48 Weeks</measure>
    <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
    <description>Change From Baseline in Trough Forced Expiratory Volume in 1 second (FEV1) after 48 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score, Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</measure>
    <time_frame>Week 48</time_frame>
    <description>Rating scale of 3 domains - symptoms, activities and impact (weighted). Worst score = 100, best score = 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TDI Focal Score, Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI) (Combined Studies)</measure>
    <time_frame>Week 48</time_frame>
    <description>Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9
For this endpoint data of twin studies NCT00168844 and NCT00168831 was combined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COPD Exacerbation Rate, Safety Set (SS) (Combined Studies)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of Chronic Obstructive Pulmonary Disease (COPD) exacerbations per patient year
For this endpoint data of the twin studies NCT00168844 and NCT00168831 was combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline to Week 40 pre-dose</time_frame>
    <description>Week 40 pre-dose - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR Interval</measure>
    <time_frame>Baseline to Week 40 pre-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QRS Interval</measure>
    <time_frame>Baseline to Week 40 pre-dose</time_frame>
    <description>Week 40 pre-dose - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QT Interval</measure>
    <time_frame>Baseline to Week 40 pre-dose</time_frame>
    <description>Week 40 pre-dose - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QT Interval (Bazett)</measure>
    <time_frame>Baseline to Week 40 pre-dose</time_frame>
    <description>Week 40 pre-dose - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QT Interval (Fridericia)</measure>
    <time_frame>Baseline to Week 40 pre-dose</time_frame>
    <description>Week 40 pre-dose - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Supraventricular Premature Beat (SVPB) Total</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SVPB Run Events</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SVPB Pairs</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ventricular Premature Beat (VPB) Total</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ventricular Premature Beat (VPB) Run Events</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VPB Pairs</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Week 40 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Haematocrit, Packed Cell Volume (PCV)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Haemoglobin</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Red Blood Cell Count</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in White Blood Cell Count</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelets</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neutrophils</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neutrophils (Absolute)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eosinophils (Absolute)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Basophils (Absolute)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lymphocytes (Absolute)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monocytes (Absolute)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calcium</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphate</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Transaminase/Glutamic-oxaloacetic Transaminase (AST/GOT), Serum Glutamic-oxaloacetic Transaminase (SGOT)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Transaminase/Glutamic Pyruvate Transaminase (ALT/GPT), Serum Glutamate Pyruvate Transaminase (SGPT)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lactic Dehyrogenase (LDH)</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucose</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urea</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Urea Nitrogen</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bilirubin, Total</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Uric Acid</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Protein, Total</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin</measure>
    <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
    <description>Week 48 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FEV1 After 2, 8, 16, 24, 32 and 40 Weeks</measure>
    <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
    <description>Change From Baseline in Trough Forced Expiratory Volume in 1 second (FEV1) after 2, 8, 16, 24, 32 and 40 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FVC After 2, 8, 16, 24, 32, 40 and 48 Weeks</measure>
    <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
    <description>Change From Baseline in Trough Forced vital capacity (FVC) after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 AUC0-3 After 2, 8, 16, 24, 32, 40 and 48 Weeks</measure>
    <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
    <description>FEV1 AUC0-3 represents the Area under Curve over the time interval from 0 to 3 hours after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FVC AUC0-3 After 2, 8, 16, 24, 32, 40 and 48 Weeks</measure>
    <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
    <description>FVC AUC0-3 represents the Area under Curve over the time interval from 0 to 3 hours after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Morning Pre-dose PEFRs</measure>
    <time_frame>Weeks 2, 8, 16, 24, 32, 40, 48</time_frame>
    <description>Weekly mean morning pre-dose peak expiratory flow rates (PEFRs). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Morning Evening PEFRs</measure>
    <time_frame>Weeks 2, 8, 16, 24, 32, 40, 48</time_frame>
    <description>Weekly mean evening peak expiratory flow rates (PEFRs). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Number of Puffs of Rescue Medication Per Day</measure>
    <time_frame>Weeks 2, 8, 16, 24, 32, 40, 48</time_frame>
    <description>Weekly mean number of puffs of rescue medication used per day as required (PRN salbutamol). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler TDI Scores</measure>
    <time_frame>Week 48</time_frame>
    <description>Mahler Transitional Dyspnoea Index (TDI) scores measured as change in functional impairment, change in magnitude of tasks and change in magnitude of efforts over the treatment period. The means are adjusted for centre, smoking status at entry and baseline value.
Worst score = -3, best score = +3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Scores</measure>
    <time_frame>Week 48</time_frame>
    <description>Saint George's Respiratory Questionnaire (SGRQ) Scores impacts, activities and symptoms. Worst score = 100, best score = 0.
The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptoms Scores</measure>
    <time_frame>Week 48</time_frame>
    <description>COPD symptoms Scores - wheezing, shortness of breath, coughing and tightness of chest over the treatment period.
Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGE Scores</measure>
    <time_frame>Week 48</time_frame>
    <description>Physician's Global evaluation (PGE) scores over the treatment period. Scale: 1−2 = Poor, 3−4 = Fair, 5−6 = Good, 7−8 = Excellent The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGR Scores</measure>
    <time_frame>Week 48</time_frame>
    <description>Patient's Global rating (PGR) scores over the treatment period. Scale: 1=much better to 7=much worse The means are adjusted for centre, smoking status at entry and baseline value.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1007</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium Respimat 5mcg (Tio R5)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Respimat 10mcg (Tio R10)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Inhalation Solution</intervention_name>
    <arm_group_label>Tiotropium Respimat 5mcg (Tio R5)</arm_group_label>
    <arm_group_label>Tiotropium Respimat 10mcg (Tio R10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria

          -  Patients with stable moderate to severe COPD and a smoking history of at least 10 pack
             years were eligible for inclusion in the study. Patients with significant diseases
             other than COPD were excluded as were patients with a recent history of myocardial
             infarction, history of malignancy, unstable or life-threatening cardiac arrhythmia,
             narrow-angle glaucoma, asthma or other allergic conditions. Patients treated with
             cromolyn, nedocromil, oral beta-adrenergics or unstable doses of oral corticosteroids
             were ineligible for inclusion in the study as were patients who had received previous
             treatment with tiotropium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hallandale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mittersill</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwechat</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumgartner Hohe Otto Wagner Spital Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lappeenranta</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lohja</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amboise cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 06</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Metz cedex 01</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mournies-Chania</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trikala</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bussolengo (vr)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cava dei tirreni (SA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Crema (CR)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pistoia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sesto San Giovanni (Milano)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerenveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vanderbijlpark</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sant Boi de Llobregat (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Babbacombe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isleworth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>January 30, 2009</results_first_submitted>
  <results_first_submitted_qc>September 4, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2009</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium Respimat 5mcg (Tio R5)</title>
          <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Respimat 10mcg (Tio R10)</title>
          <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="335"/>
                <participants group_id="P3" count="334"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium Respimat 5mcg</title>
          <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Respimat 10mcg</title>
          <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="338"/>
            <count group_id="B2" value="335"/>
            <count group_id="B3" value="334"/>
            <count group_id="B4" value="1007"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="8.9"/>
                    <measurement group_id="B2" value="65.6" spread="8.6"/>
                    <measurement group_id="B3" value="65.7" spread="8.4"/>
                    <measurement group_id="B4" value="65.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="235"/>
                    <measurement group_id="B4" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 After 48 Weeks</title>
        <description>Change From Baseline in Trough Forced Expiratory Volume in 1 second (FEV1) after 48 weeks</description>
        <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
        <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 After 48 Weeks</title>
          <description>Change From Baseline in Trough Forced Expiratory Volume in 1 second (FEV1) after 48 weeks</description>
          <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.077" spread="0.012"/>
                    <measurement group_id="O2" value="0.105" spread="0.012"/>
                    <measurement group_id="O3" value="-0.036" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry, centre and baseline value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry,centre and baseline value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score, Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</title>
        <description>Rating scale of 3 domains - symptoms, activities and impact (weighted). Worst score = 100, best score = 0</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire (SGRQ) Total Score, Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</title>
          <description>Rating scale of 3 domains - symptoms, activities and impact (weighted). Worst score = 100, best score = 0</description>
          <population>Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.771" spread="0.718"/>
                    <measurement group_id="O2" value="40.038" spread="0.726"/>
                    <measurement group_id="O3" value="43.484" spread="0.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>The means are adjusted for centre, smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.713</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.052</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <method_desc>The means are adjusted for centre, smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.445</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TDI Focal Score, Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI) (Combined Studies)</title>
        <description>Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9
For this endpoint data of twin studies NCT00168844 and NCT00168831 was combined.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>TDI Focal Score, Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI) (Combined Studies)</title>
          <description>Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9
For this endpoint data of twin studies NCT00168844 and NCT00168831 was combined.</description>
          <population>Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="618"/>
                <count group_id="O3" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.890" spread="0.112"/>
                    <measurement group_id="O2" value="1.913" spread="0.113"/>
                    <measurement group_id="O3" value="0.837" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The means are adjusted for centre, smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.165</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The means are adjusted for centre, smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.166</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>COPD Exacerbation Rate, Safety Set (SS) (Combined Studies)</title>
        <description>Number of Chronic Obstructive Pulmonary Disease (COPD) exacerbations per patient year
For this endpoint data of the twin studies NCT00168844 and NCT00168831 was combined.</description>
        <time_frame>48 weeks</time_frame>
        <population>Safety Set. Combined analysis of studies NCT00168844 and NCT00168831. 670 patients analysed in total comprises 338 patients from NCT00168831 and 332 patients from study NCT00168844, 667 patients - 335 and 332, 653 patients - 334 and 319 respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbation Rate, Safety Set (SS) (Combined Studies)</title>
          <description>Number of Chronic Obstructive Pulmonary Disease (COPD) exacerbations per patient year
For this endpoint data of the twin studies NCT00168844 and NCT00168831 was combined.</description>
          <population>Safety Set. Combined analysis of studies NCT00168844 and NCT00168831. 670 patients analysed in total comprises 338 patients from NCT00168831 and 332 patients from study NCT00168844, 667 patients - 335 and 332, 653 patients - 334 and 319 respectively.</population>
          <units>Number of exacerbations per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="670"/>
                <count group_id="O2" value="667"/>
                <count group_id="O3" value="653"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="2.02"/>
                    <measurement group_id="O2" value="1.02" spread="3.05"/>
                    <measurement group_id="O3" value="1.91" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Poisson regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.782</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.687</ci_lower_limit>
            <ci_upper_limit>0.890</ci_upper_limit>
            <estimate_desc>Tiotropium Respimat 5mcg vs. Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.725</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.635</ci_lower_limit>
            <ci_upper_limit>0.828</ci_upper_limit>
            <estimate_desc>Tiotropium Respimat 10mcg vs. Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate</title>
        <description>Week 40 pre-dose - baseline</description>
        <time_frame>Baseline to Week 40 pre-dose</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead electrocardiogram (ECG) and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate</title>
          <description>Week 40 pre-dose - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead electrocardiogram (ECG) and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="12.4"/>
                    <measurement group_id="O2" value="3.6" spread="10.5"/>
                    <measurement group_id="O3" value="1.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR Interval</title>
        <time_frame>Baseline to Week 40 pre-dose</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead electrocardiogram (ECG) and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR Interval</title>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead electrocardiogram (ECG) and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="20.2"/>
                    <measurement group_id="O2" value="-2.5" spread="15.1"/>
                    <measurement group_id="O3" value="-0.5" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QRS Interval</title>
        <description>Week 40 pre-dose - baseline</description>
        <time_frame>Baseline to Week 40 pre-dose</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QRS Interval</title>
          <description>Week 40 pre-dose - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="9.4"/>
                    <measurement group_id="O2" value="1.7" spread="12.1"/>
                    <measurement group_id="O3" value="-1.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QT Interval</title>
        <description>Week 40 pre-dose - baseline</description>
        <time_frame>Baseline to Week 40 pre-dose</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QT Interval</title>
          <description>Week 40 pre-dose - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="26.5"/>
                    <measurement group_id="O2" value="-3.5" spread="25.2"/>
                    <measurement group_id="O3" value="-3.2" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QT Interval (Bazett)</title>
        <description>Week 40 pre-dose - baseline</description>
        <time_frame>Baseline to Week 40 pre-dose</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QT Interval (Bazett)</title>
          <description>Week 40 pre-dose - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="29.9"/>
                    <measurement group_id="O2" value="5.4" spread="24.0"/>
                    <measurement group_id="O3" value="2.5" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QT Interval (Fridericia)</title>
        <description>Week 40 pre-dose - baseline</description>
        <time_frame>Baseline to Week 40 pre-dose</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QT Interval (Fridericia)</title>
          <description>Week 40 pre-dose - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="24.3"/>
                    <measurement group_id="O2" value="2.2" spread="21.3"/>
                    <measurement group_id="O3" value="0.5" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="5.4"/>
                    <measurement group_id="O2" value="1.2" spread="6.4"/>
                    <measurement group_id="O3" value="0.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Supraventricular Premature Beat (SVPB) Total</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Supraventricular Premature Beat (SVPB) Total</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>premature beats per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="94.2"/>
                    <measurement group_id="O2" value="6.8" spread="87.4"/>
                    <measurement group_id="O3" value="20.9" spread="125.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SVPB Run Events</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SVPB Run Events</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>events per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.6"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                    <measurement group_id="O3" value="-0.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SVPB Pairs</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SVPB Pairs</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>pairs per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="4.0"/>
                    <measurement group_id="O2" value="-0.2" spread="2.3"/>
                    <measurement group_id="O3" value="2.0" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ventricular Premature Beat (VPB) Total</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ventricular Premature Beat (VPB) Total</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>premature beats per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="105.9"/>
                    <measurement group_id="O2" value="4.6" spread="68.8"/>
                    <measurement group_id="O3" value="-24.1" spread="182.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ventricular Premature Beat (VPB) Run Events</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ventricular Premature Beat (VPB) Run Events</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>events per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VPB Pairs</title>
        <description>Week 40 - baseline</description>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VPB Pairs</title>
          <description>Week 40 - baseline</description>
          <population>Combined analysis of studies NCT00168844 and NCT00168831 in subset of patients who had additional 12-lead ECG and 24-hour Holter monitoring performed (see protocol and clinical trial report)</population>
          <units>pairs per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.6"/>
                    <measurement group_id="O2" value="-0.1" spread="3.8"/>
                    <measurement group_id="O3" value="-0.9" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Haematocrit, Packed Cell Volume (PCV)</title>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Haematocrit, Packed Cell Volume (PCV)</title>
          <population>Safety Set</population>
          <units>Percentage of erythrocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="4"/>
                    <measurement group_id="O2" value="0" spread="4"/>
                    <measurement group_id="O3" value="0" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Haemoglobin</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Haemoglobin</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>grams per litre (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="280"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="11"/>
                    <measurement group_id="O2" value="-1" spread="10"/>
                    <measurement group_id="O3" value="-1" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Red Blood Cell Count</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Red Blood Cell Count</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^12/Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.3"/>
                    <measurement group_id="O3" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in White Blood Cell Count</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cell Count</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="280"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.7"/>
                    <measurement group_id="O2" value="0.3" spread="1.5"/>
                    <measurement group_id="O3" value="0.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelets</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="31"/>
                    <measurement group_id="O2" value="3" spread="29"/>
                    <measurement group_id="O3" value="0" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neutrophils</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neutrophils</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="8"/>
                    <measurement group_id="O2" value="1" spread="8"/>
                    <measurement group_id="O3" value="0" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                    <measurement group_id="O3" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="4"/>
                    <measurement group_id="O2" value="-1" spread="4"/>
                    <measurement group_id="O3" value="0" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="4"/>
                    <measurement group_id="O2" value="0" spread="4"/>
                    <measurement group_id="O3" value="0" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neutrophils (Absolute)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neutrophils (Absolute)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.9"/>
                    <measurement group_id="O2" value="0.3" spread="1.6"/>
                    <measurement group_id="O3" value="0.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eosinophils (Absolute)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eosinophils (Absolute)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Basophils (Absolute)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils (Absolute)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lymphocytes (Absolute)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes (Absolute)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monocytes (Absolute)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes (Absolute)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.3"/>
                    <measurement group_id="O3" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calcium</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calcium</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>millimoles per litre (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Phosphate</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphate</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.23"/>
                    <measurement group_id="O2" value="0.00" spread="0.24"/>
                    <measurement group_id="O3" value="0.02" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Transaminase/Glutamic-oxaloacetic Transaminase (AST/GOT), Serum Glutamic-oxaloacetic Transaminase (SGOT)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Transaminase/Glutamic-oxaloacetic Transaminase (AST/GOT), Serum Glutamic-oxaloacetic Transaminase (SGOT)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>Units per litre (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="20"/>
                    <measurement group_id="O2" value="-1" spread="25"/>
                    <measurement group_id="O3" value="-2" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Transaminase/Glutamic Pyruvate Transaminase (ALT/GPT), Serum Glutamate Pyruvate Transaminase (SGPT)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Transaminase/Glutamic Pyruvate Transaminase (ALT/GPT), Serum Glutamate Pyruvate Transaminase (SGPT)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="18"/>
                    <measurement group_id="O2" value="-1" spread="18"/>
                    <measurement group_id="O3" value="-1" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="19"/>
                    <measurement group_id="O2" value="-5" spread="23"/>
                    <measurement group_id="O3" value="-3" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lactic Dehyrogenase (LDH)</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lactic Dehyrogenase (LDH)</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="40"/>
                    <measurement group_id="O2" value="3" spread="44"/>
                    <measurement group_id="O3" value="5" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucose</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="280"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="2.11"/>
                    <measurement group_id="O2" value="0.26" spread="2.17"/>
                    <measurement group_id="O3" value="0.10" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urea</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urea</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.9"/>
                    <measurement group_id="O2" value="0.0" spread="2.1"/>
                    <measurement group_id="O3" value="0.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Urea Nitrogen</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Urea Nitrogen</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>milligrams per decilitre (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.0"/>
                    <measurement group_id="O2" value="0.0" spread="3.3"/>
                    <measurement group_id="O3" value="0.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>micromoles per litre (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="9.3"/>
                    <measurement group_id="O2" value="1.5" spread="12.2"/>
                    <measurement group_id="O3" value="2.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bilirubin, Total</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bilirubin, Total</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.2"/>
                    <measurement group_id="O2" value="0.4" spread="4.2"/>
                    <measurement group_id="O3" value="-0.1" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Uric Acid</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Uric Acid</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.41" spread="80.08"/>
                    <measurement group_id="O2" value="9.39" spread="85.92"/>
                    <measurement group_id="O3" value="6.52" spread="76.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Protein, Total</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Protein, Total</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>grams per litre (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="5"/>
                    <measurement group_id="O2" value="-1" spread="5"/>
                    <measurement group_id="O3" value="-1" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin</title>
        <description>Week 48 - baseline</description>
        <time_frame>Baseline to Week 48 or at premature discontinuation if before Week 48</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin</title>
          <description>Week 48 - baseline</description>
          <population>Safety Set</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="4"/>
                    <measurement group_id="O2" value="1" spread="4"/>
                    <measurement group_id="O3" value="1" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FEV1 After 2, 8, 16, 24, 32 and 40 Weeks</title>
        <description>Change From Baseline in Trough Forced Expiratory Volume in 1 second (FEV1) after 2, 8, 16, 24, 32 and 40 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
        <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 After 2, 8, 16, 24, 32 and 40 Weeks</title>
          <description>Change From Baseline in Trough Forced Expiratory Volume in 1 second (FEV1) after 2, 8, 16, 24, 32 and 40 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" spread="0.010"/>
                    <measurement group_id="O2" value="0.114" spread="0.010"/>
                    <measurement group_id="O3" value="-0.003" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.011"/>
                    <measurement group_id="O2" value="0.133" spread="0.011"/>
                    <measurement group_id="O3" value="-0.012" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.012"/>
                    <measurement group_id="O2" value="0.132" spread="0.012"/>
                    <measurement group_id="O3" value="-0.008" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="0.012"/>
                    <measurement group_id="O2" value="0.132" spread="0.012"/>
                    <measurement group_id="O3" value="-0.010" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.012"/>
                    <measurement group_id="O2" value="0.145" spread="0.012"/>
                    <measurement group_id="O3" value="-0.012" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.012"/>
                    <measurement group_id="O2" value="0.106" spread="0.012"/>
                    <measurement group_id="O3" value="-0.027" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FVC After 2, 8, 16, 24, 32, 40 and 48 Weeks</title>
        <description>Change From Baseline in Trough Forced vital capacity (FVC) after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
        <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FVC After 2, 8, 16, 24, 32, 40 and 48 Weeks</title>
          <description>Change From Baseline in Trough Forced vital capacity (FVC) after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.257" spread="0.021"/>
                    <measurement group_id="O2" value="0.264" spread="0.022"/>
                    <measurement group_id="O3" value="0.009" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.207" spread="0.023"/>
                    <measurement group_id="O2" value="0.266" spread="0.023"/>
                    <measurement group_id="O3" value="-0.007" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.259" spread="0.025"/>
                    <measurement group_id="O2" value="0.266" spread="0.025"/>
                    <measurement group_id="O3" value="-0.002" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.236" spread="0.025"/>
                    <measurement group_id="O2" value="0.274" spread="0.025"/>
                    <measurement group_id="O3" value="0.008" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" spread="0.026"/>
                    <measurement group_id="O2" value="0.286" spread="0.026"/>
                    <measurement group_id="O3" value="-0.008" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.211" spread="0.025"/>
                    <measurement group_id="O2" value="0.207" spread="0.025"/>
                    <measurement group_id="O3" value="-0.028" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread="0.026"/>
                    <measurement group_id="O2" value="0.209" spread="0.026"/>
                    <measurement group_id="O3" value="-0.043" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry, centre and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.240</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.252</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 AUC0-3 After 2, 8, 16, 24, 32, 40 and 48 Weeks</title>
        <description>FEV1 AUC0-3 represents the Area under Curve over the time interval from 0 to 3 hours after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
        <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 AUC0-3 After 2, 8, 16, 24, 32, 40 and 48 Weeks</title>
          <description>FEV1 AUC0-3 represents the Area under Curve over the time interval from 0 to 3 hours after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.246" spread="0.011"/>
                    <measurement group_id="O2" value="0.257" spread="0.011"/>
                    <measurement group_id="O3" value="0.044" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.234" spread="0.012"/>
                    <measurement group_id="O2" value="0.258" spread="0.012"/>
                    <measurement group_id="O3" value="0.037" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.235" spread="0.012"/>
                    <measurement group_id="O2" value="0.242" spread="0.012"/>
                    <measurement group_id="O3" value="0.026" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.222" spread="0.012"/>
                    <measurement group_id="O2" value="0.245" spread="0.012"/>
                    <measurement group_id="O3" value="0.024" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.198" spread="0.013"/>
                    <measurement group_id="O2" value="0.241" spread="0.013"/>
                    <measurement group_id="O3" value="0.018" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread="0.012"/>
                    <measurement group_id="O2" value="0.206" spread="0.012"/>
                    <measurement group_id="O3" value="-0.000" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" spread="0.013"/>
                    <measurement group_id="O2" value="0.210" spread="0.013"/>
                    <measurement group_id="O3" value="-0.002" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry, centre and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry, centre and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.212</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FVC AUC0-3 After 2, 8, 16, 24, 32, 40 and 48 Weeks</title>
        <description>FVC AUC0-3 represents the Area under Curve over the time interval from 0 to 3 hours after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>10 minutes prior to test-drug inhalation and at 5, 30 and 60 minutes and 2 and 3 hours after inhalation of study medication</time_frame>
        <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FVC AUC0-3 After 2, 8, 16, 24, 32, 40 and 48 Weeks</title>
          <description>FVC AUC0-3 represents the Area under Curve over the time interval from 0 to 3 hours after 2, 8, 16, 24, 32, 40 and 48 weeks. The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Clinic Spirometry (FAS-PFT)</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.513" spread="0.024"/>
                    <measurement group_id="O2" value="0.522" spread="0.024"/>
                    <measurement group_id="O3" value="0.140" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.463" spread="0.026"/>
                    <measurement group_id="O2" value="0.521" spread="0.026"/>
                    <measurement group_id="O3" value="0.117" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.466" spread="0.026"/>
                    <measurement group_id="O2" value="0.488" spread="0.026"/>
                    <measurement group_id="O3" value="0.108" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.468" spread="0.027"/>
                    <measurement group_id="O2" value="0.498" spread="0.027"/>
                    <measurement group_id="O3" value="0.092" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.438" spread="0.027"/>
                    <measurement group_id="O2" value="0.477" spread="0.027"/>
                    <measurement group_id="O3" value="0.075" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.417" spread="0.027"/>
                    <measurement group_id="O2" value="0.406" spread="0.027"/>
                    <measurement group_id="O3" value="0.029" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.387" spread="0.028"/>
                    <measurement group_id="O2" value="0.411" spread="0.028"/>
                    <measurement group_id="O3" value="0.018" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry, centre and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.369</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, smoking status at entry, centre and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.393</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Morning Pre-dose PEFRs</title>
        <description>Weekly mean morning pre-dose peak expiratory flow rates (PEFRs). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
        <time_frame>Weeks 2, 8, 16, 24, 32, 40, 48</time_frame>
        <population>Full Analysis Set - Diary (FAS-DRY)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Morning Pre-dose PEFRs</title>
          <description>Weekly mean morning pre-dose peak expiratory flow rates (PEFRs). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
          <population>Full Analysis Set - Diary (FAS-DRY)</population>
          <units>Litres/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.7" spread="1.6"/>
                    <measurement group_id="O2" value="245.4" spread="1.6"/>
                    <measurement group_id="O3" value="226.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.4" spread="2.3"/>
                    <measurement group_id="O2" value="253.9" spread="2.3"/>
                    <measurement group_id="O3" value="229.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.5" spread="2.8"/>
                    <measurement group_id="O2" value="258.4" spread="2.8"/>
                    <measurement group_id="O3" value="231.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.5" spread="3.2"/>
                    <measurement group_id="O2" value="263.8" spread="3.2"/>
                    <measurement group_id="O3" value="230.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.5" spread="3.2"/>
                    <measurement group_id="O2" value="264.6" spread="3.2"/>
                    <measurement group_id="O3" value="232.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.7" spread="3.2"/>
                    <measurement group_id="O2" value="264.7" spread="3.2"/>
                    <measurement group_id="O3" value="231.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.3" spread="3.4"/>
                    <measurement group_id="O2" value="264.1" spread="3.4"/>
                    <measurement group_id="O3" value="232.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, centre,smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, centre,smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>31.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Morning Evening PEFRs</title>
        <description>Weekly mean evening peak expiratory flow rates (PEFRs). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
        <time_frame>Weeks 2, 8, 16, 24, 32, 40, 48</time_frame>
        <population>Full Analysis Set - Diary (FAS-DRY)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Morning Evening PEFRs</title>
          <description>Weekly mean evening peak expiratory flow rates (PEFRs). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
          <population>Full Analysis Set - Diary (FAS-DRY)</population>
          <units>Litres/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.7" spread="1.7"/>
                    <measurement group_id="O2" value="265.0" spread="1.7"/>
                    <measurement group_id="O3" value="237.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.9" spread="2.5"/>
                    <measurement group_id="O2" value="273.5" spread="2.5"/>
                    <measurement group_id="O3" value="240.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.7" spread="3.0"/>
                    <measurement group_id="O2" value="276.3" spread="3.0"/>
                    <measurement group_id="O3" value="240.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.5" spread="3.2"/>
                    <measurement group_id="O2" value="280.3" spread="3.2"/>
                    <measurement group_id="O3" value="241.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.6" spread="3.3"/>
                    <measurement group_id="O2" value="279.7" spread="3.2"/>
                    <measurement group_id="O3" value="241.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.0" spread="3.3"/>
                    <measurement group_id="O2" value="280.5" spread="3.2"/>
                    <measurement group_id="O3" value="240.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.0" spread="3.4"/>
                    <measurement group_id="O2" value="281.0" spread="3.4"/>
                    <measurement group_id="O3" value="241.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, centre,smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, centre,smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>39.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Number of Puffs of Rescue Medication Per Day</title>
        <description>Weekly mean number of puffs of rescue medication used per day as required (PRN salbutamol). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
        <time_frame>Weeks 2, 8, 16, 24, 32, 40, 48</time_frame>
        <population>Full Analysis Set - Diary (FAS-DRY)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Number of Puffs of Rescue Medication Per Day</title>
          <description>Weekly mean number of puffs of rescue medication used per day as required (PRN salbutamol). The means are adjusted for centre, smoking status at entry, and baseline value.</description>
          <population>Full Analysis Set - Diary (FAS-DRY)</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.1"/>
                    <measurement group_id="O2" value="2.0" spread="0.1"/>
                    <measurement group_id="O3" value="2.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.1"/>
                    <measurement group_id="O2" value="2.0" spread="0.1"/>
                    <measurement group_id="O3" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.1"/>
                    <measurement group_id="O2" value="2.1" spread="0.1"/>
                    <measurement group_id="O3" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.1"/>
                    <measurement group_id="O2" value="2.3" spread="0.1"/>
                    <measurement group_id="O3" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.1"/>
                    <measurement group_id="O2" value="2.3" spread="0.1"/>
                    <measurement group_id="O3" value="3.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.1"/>
                    <measurement group_id="O2" value="2.4" spread="0.1"/>
                    <measurement group_id="O3" value="3.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.1"/>
                    <measurement group_id="O2" value="2.5" spread="0.1"/>
                    <measurement group_id="O3" value="3.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0169</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, centre,smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 5mcg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis for week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA analysis with terms for treatment, centre,smoking status at entry and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Tiotropium Respimat 10mcg - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler TDI Scores</title>
        <description>Mahler Transitional Dyspnoea Index (TDI) scores measured as change in functional impairment, change in magnitude of tasks and change in magnitude of efforts over the treatment period. The means are adjusted for centre, smoking status at entry and baseline value.
Worst score = -3, best score = +3</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler TDI Scores</title>
          <description>Mahler Transitional Dyspnoea Index (TDI) scores measured as change in functional impairment, change in magnitude of tasks and change in magnitude of efforts over the treatment period. The means are adjusted for centre, smoking status at entry and baseline value.
Worst score = -3, best score = +3</description>
          <population>Full Analysis Set - Transitional Dyspnoea Index (FAS-TDI)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="305"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Functional Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.630" spread="0.057"/>
                    <measurement group_id="O2" value="0.577" spread="0.057"/>
                    <measurement group_id="O3" value="0.318" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnitude of Task</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" spread="0.057"/>
                    <measurement group_id="O2" value="0.621" spread="0.057"/>
                    <measurement group_id="O3" value="0.275" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnitude of Effort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.604" spread="0.061"/>
                    <measurement group_id="O2" value="0.594" spread="0.062"/>
                    <measurement group_id="O3" value="0.264" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire (SGRQ) Scores</title>
        <description>Saint George's Respiratory Questionnaire (SGRQ) Scores impacts, activities and symptoms. Worst score = 100, best score = 0.
The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire (SGRQ) Scores</title>
          <description>Saint George's Respiratory Questionnaire (SGRQ) Scores impacts, activities and symptoms. Worst score = 100, best score = 0.
The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Saint George's Respiratory Questionnaire (FAS-QOL)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.680" spread="1.116"/>
                    <measurement group_id="O2" value="42.108" spread="1.128"/>
                    <measurement group_id="O3" value="48.244" spread="1.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.529" spread="0.897"/>
                    <measurement group_id="O2" value="57.045" spread="0.906"/>
                    <measurement group_id="O3" value="60.921" spread="0.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.858" spread="0.783"/>
                    <measurement group_id="O2" value="29.532" spread="0.791"/>
                    <measurement group_id="O3" value="32.239" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptoms Scores</title>
        <description>COPD symptoms Scores - wheezing, shortness of breath, coughing and tightness of chest over the treatment period.
Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - COPD symptoms (FAS-SYM)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptoms Scores</title>
          <description>COPD symptoms Scores - wheezing, shortness of breath, coughing and tightness of chest over the treatment period.
Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - COPD symptoms (FAS-SYM)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.04"/>
                    <measurement group_id="O2" value="0.72" spread="0.04"/>
                    <measurement group_id="O3" value="0.85" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.04"/>
                    <measurement group_id="O2" value="1.41" spread="0.04"/>
                    <measurement group_id="O3" value="1.61" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coughing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.04"/>
                    <measurement group_id="O2" value="1.05" spread="0.04"/>
                    <measurement group_id="O3" value="1.06" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tightness of Chest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.04"/>
                    <measurement group_id="O2" value="0.55" spread="0.04"/>
                    <measurement group_id="O3" value="0.64" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PGE Scores</title>
        <description>Physician's Global evaluation (PGE) scores over the treatment period. Scale: 1−2 = Poor, 3−4 = Fair, 5−6 = Good, 7−8 = Excellent The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - Physician's Global Evaluation (FAS-PGE)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>PGE Scores</title>
          <description>Physician's Global evaluation (PGE) scores over the treatment period. Scale: 1−2 = Poor, 3−4 = Fair, 5−6 = Good, 7−8 = Excellent The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Physician's Global Evaluation (FAS-PGE)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="0.06"/>
                    <measurement group_id="O2" value="4.84" spread="0.06"/>
                    <measurement group_id="O3" value="4.44" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PGR Scores</title>
        <description>Patient's Global rating (PGR) scores over the treatment period. Scale: 1=much better to 7=much worse The means are adjusted for centre, smoking status at entry and baseline value.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set - Patient's Global Rating (FAS-PGR)</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 5mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 10mcg</title>
            <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>PGR Scores</title>
          <description>Patient's Global rating (PGR) scores over the treatment period. Scale: 1=much better to 7=much worse The means are adjusted for centre, smoking status at entry and baseline value.</description>
          <population>Full Analysis Set - Patient's Global Rating (FAS-PGR)</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="0.08"/>
                    <measurement group_id="O2" value="2.94" spread="0.08"/>
                    <measurement group_id="O3" value="3.42" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium Respimat 5mcg</title>
          <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (5 mcg)</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium Respimat 10mcg</title>
          <description>Tiotropium Bromide inhalation solution delivered from Respimat Inhaler (10 mcg)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo inhalation solution delivered from Respimat Inhaler (matching placebo)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63"/>
                <counts group_id="E2" subjects_affected="72"/>
                <counts group_id="E3" subjects_affected="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Jejunal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neurogenic bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Temporal lobe epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Tension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Dyspnoea exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Postoperative care</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177"/>
                <counts group_id="E2" subjects_affected="174"/>
                <counts group_id="E3" subjects_affected="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive airways disease exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="335"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

